JPS61263999A - Novel peptide - Google Patents
Novel peptideInfo
- Publication number
- JPS61263999A JPS61263999A JP60107884A JP10788485A JPS61263999A JP S61263999 A JPS61263999 A JP S61263999A JP 60107884 A JP60107884 A JP 60107884A JP 10788485 A JP10788485 A JP 10788485A JP S61263999 A JPS61263999 A JP S61263999A
- Authority
- JP
- Japan
- Prior art keywords
- osteocalcin
- formula
- gla
- bone
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
発明の利用分野
本発明は骨代謝の状態を知る上での重要な指標となる標
識試薬として有用なオステオカルシンペプチドに関する
。DETAILED DESCRIPTION OF THE INVENTION Field of Application of the Invention The present invention relates to an osteocalcin peptide useful as a labeling reagent that is an important indicator for understanding the state of bone metabolism.
従来技術
オステオカルシンは、石灰化骨tこ多く含まれ、ビタミ
ンに依存性Ca結合アミノ酸であるGla(r−カルボ
キシグルタミン酸)を含むタンパク質であり、骨Gla
タンパク質(BGP )ともいい、現在までに、ヒト、
ウシ、メカジキ、猫、ウシ、ニワトリ、ラットが知られ
ている( Pr1ce、P、A、。Prior Art Osteocalcin is a protein that contains a large amount of mineralized bone and contains Gla (r-carboxyglutamic acid), a vitamin-dependent Ca-binding amino acid.
Also known as protein (BGP), to date, human,
Cows, swordfish, cats, cows, chickens, and rats are known (Pr1ce, P.A.).
etal Proc、Natl、Acad、Sci、
U、S、、 73 、33711〜3373、(/り7
乙) HShimomura、 H,、etal、 J
。etal Proc, Natl, Acad, Sci,
U, S,, 73, 33711-3373, (/ri7
B) H Shimomura, H, etal, J
.
Biochem、、 ?乙、’10!;−’II/、
(/デ、r4’)〕。また天然オステオカルシンから誘
導された標識および抗体を利用するラジオイムノアッセ
イ1こ関しても記載されているC Pr1ce、 P、
A、 、 etal、 J。Biochem...? Otsu, '10! ;-'II/,
(/de, r4')]. Radioimmunoassays utilizing labels and antibodies derived from natural osteocalcin have also been described.
A., etal, J.
Cl1n、 Invest、At g7gNl#3(/
りg。Cl1n, Invest, At g7gNl#3(/
Rig.
)〕。)].
発明が解決しようとする問題点
本発明者らは犬の皮質骨からオステオカルシンを単離、
精製し、その構造を決定して新規物質であることを確認
した。Problems to be Solved by the Invention The present inventors isolated osteocalcin from cortical bone of dogs.
They purified it, determined its structure, and confirmed that it was a new substance.
問題点を解決するための手段
本発明は、上記知見に基づいて成されたものでPro−
Leu−Gla−Pro−Lys−Arg−Gla−7
“I −C,y、s −G Io−1°“−”“−1゛
°−”°”−Cys−Asp−Glu−Leu−Ala
−Asp−His−11e−Gly−Phe−OH[:
I)(式中、T戸はL−チロシン、LeuはL−ロイシ
ン、AspはL−アスパラギン酸、SerはL−セリン
、Glyはグリシン、AlaはL−アラニン、Proは
L−プロリン、Glaはr−カルボキシグルタミン酸、
LysはL−リジン、ArgはL−アルギニン、Val
はL−バリン、CysはL−システィン、AsnはL−
アスパラギン、HisはL−ヒスチジン、IleはL−
イソロイシン、PheはL−フェニルアラニンを示す)
で表されるペプチドまたはその塩である。Means for Solving the Problems The present invention has been made based on the above knowledge, and is based on the above findings.
Leu-Gla-Pro-Lys-Arg-Gla-7
"I -C,y,s -G Io-1°"-""-1゛°-"°"-Cys-Asp-Glu-Leu-Ala
-Asp-His-11e-Gly-Phe-OH[:
I) (In the formula, T is L-tyrosine, Leu is L-leucine, Asp is L-aspartic acid, Ser is L-serine, Gly is glycine, Ala is L-alanine, Pro is L-proline, and Gla is r-carboxyglutamic acid,
Lys is L-lysine, Arg is L-arginine, Val
is L-valine, Cys is L-cystine, Asn is L-
asparagine, His is L-histidine, Ile is L-
isoleucine (Phe indicates L-phenylalanine) or a salt thereof.
まず本発明を実施するに当って犬の骨から抽出して単離
、精製してもよく、さら(こ本発明の式〔I〕で表わさ
れるペプチドの構造に基づぎ常法により合成してもよい
。First, in carrying out the present invention, the peptide may be extracted from dog bones, isolated, and purified. It's okay.
以下eこ抽出法tこよる例を述べる。An example of the extraction method will be described below.
例えば、犬の骨を脱脂乾燥した後、すりつぶし、EDT
八等の溶液で脱灰抽出し、遠心分離等で、上清を集め、
透析膜等(こよって脱塩し分離され、ゲ/l/ ?濾過
及び高速液体クロマトグラフィーtこより分離精製され
る。For example, after degreasing and drying dog bones, grind them and use EDT.
Demineralize and extract with a solution of No. 8, collect the supernatant by centrifugation, etc.
It is desalted and separated using a dialysis membrane, etc., and then separated and purified by gel/l/? filtration and high performance liquid chromatography.
実施例
次tこ本発明を実施例をこより説明するが、本発明はこ
れらの実施例シこ限定されるものではない。EXAMPLES The present invention will now be described with reference to Examples, but the present invention is not limited to these Examples.
実施例 /
ピーグル大S頭の大腿骨を集め両管端を切断後内部の骨
髄を除去し、2〜37の小片tこ切断し、アセトン中、
0℃、22時間脱脂後、乾燥した。Example / Collect the femurs of the large S heads of Peagle, cut both tube ends, remove the internal bone marrow, cut into 2 to 37 small pieces, and place in acetone.
After degreasing at 0°C for 22 hours, it was dried.
乾燥骨をすりつぶし骨粉33ftを得、0.3 M E
DTA(pHgO)乙3Qmlにけん濁し、10日間
4Z℃で脱灰抽出した。これを遠心分離後<300OR
PM、10分)、上清を集め透析膜で007M炭酸水素
アンモニウムに対し透析脱塩し、凍結乾燥し、オステオ
カルシンを含有する粗成分乙lO〜を得た。これを予め
0. / M炭酸水素アンモニウムで緩衝化したセファ
デックスG−100カラム(’1. II X 7 g
on )に充填し、0. / M炭酸水素アンモニウ
ムを用いて展開した。/ 0.2 mlづつのフラクシ
ョンを分取し、これらフラクションを、2にOmμで紫
外線吸収を測定し、そのフラクション34t−5乙、3
7〜711.73〜り乙、97〜//4’、 //3〜
/112の各々を凍結乾燥した後裔々約/〜を秤量し、
2.5規定水酸化ナトリウム03m1fこ溶し、脱気、
封管後/10℃で2グ時間加水分解後アミノ酸分析した
結果、フラクション75〜り乙が1−カルボキシグルタ
ミン酸(Gla)を含有するオステオカルシン画分であ
った。Grind the dried bones to obtain 33 ft of bone powder, 0.3 M E
It was suspended in 3Qml of DTA (pHgO) and deashed and extracted at 4Z°C for 10 days. After centrifuging this <300OR
PM, 10 minutes), the supernatant was collected, desalted by dialysis against 007M ammonium bicarbonate using a dialysis membrane, and lyophilized to obtain a crude component containing osteocalcin. Set this to 0 in advance. /M ammonium bicarbonate buffered Sephadex G-100 column ('1. II x 7 g
on) and fill with 0. /M ammonium bicarbonate. / 0.2 ml fractions were collected, and the ultraviolet absorption of these fractions was measured using Omμ.
7~711.73~ri Otsu, 97~//4', //3~
After freeze-drying each of /112, approximately / ~ of the progeny was weighed,
Dissolve 03ml of 2.5N sodium hydroxide, degas,
After sealing the tube and hydrolyzing for 2 hours at 10° C., amino acid analysis revealed that fractions 75 to 2 were osteocalcin fractions containing 1-carboxyglutamic acid (Gla).
このフラクション7S−ヲ乙の凍結乾燥物(10乙mg
)を高速液体クロマトグラフィーNucleosi15
C1aのカラム(gX2!;0朋)に適用し、かつこの
カラムを流速、2mJ/minて0Z%トリフル第22
3mμで紫外線吸収の単一な吸収ピークを示すフラクシ
ョンを分取し、凍結乾燥して、以下の理化学的性質を有
する犬のオステオカルシン(1〕を得た。Freeze-dried product of this fraction 7S-Otsu (10 Otsu mg)
) for high performance liquid chromatography Nucleosi15
C1a column (g
A fraction showing a single ultraviolet absorption peak at 3 mμ was collected and freeze-dried to obtain canine osteocalcin (1) having the following physicochemical properties.
アミノ酸分析
得うした犬のオステオカルシン約/ηを乙N −)te
l / ml <溶し、/10℃、2q時間アミノ酸
分析を行うと、Leu=5とした時のアミノ酸組成(括
弧内は、理論値)は次の通りであった。Amino acid analysis obtained about canine osteocalcin/ηN-)te
Amino acid analysis was carried out at l/ml <dissolved at /10°C for 2q hours, and the amino acid composition (theoretical values in parentheses) when Leu=5 was as follows.
Asp乙O/f61,5erQり乙(+)、G I u
lA23(41゜P r o5.gg(61,G l
y291(s)、 A l a、、20ff(21+V
al/93(2)、Cys−CysOgll(1)、
I l e /(1)2(1)。Asp Otsu O/f61, 5erQ Ri Otsu (+), G I u
lA23(41゜Pro5.gg(61, G l
y291(s), Al a,, 20ff(21+V
al/93 (2), Cys-CysOgll (1),
I le /(1)2(1).
Leu !; (51,Tyr2011(2)、 P
he105(11゜Lys/15(1)、HisOり9
(+)、ArglOg(l1元素分析値
実測値C: 5.20!r% H:63g% N:/l
’Ω%計算値C:3/、9A% H:A0% N:/l
A7!;%C189H278066N46S11・3H
20(MW、 4′3乙g、乙5′)として計算した。Leu! ; (51, Tyr2011(2), P
he105 (11°Lys/15(1), HisOri9
(+), ArglOg (l1 elemental analysis value actual value C: 5.20!r% H: 63g% N: /l
'Ω% calculated value C: 3/, 9A% H: A0% N: /l
A7! ;%C189H278066N46S11・3H
It was calculated as 20 (MW, 4'3g, 5').
等電点
Bio−Rad 法によりgOμVの犬のオステオカル
シンを70%ポリアクリルアミドゲル上で、300V、
111時間、グ℃で泳動し、725%のトリクロロ酢酸
で沈澱させ、ゲルスキャナー(Isco社製 mode
l 乙3g)で、2gOpmのU■吸収を測定するとP
I=3.9であった。Using the isoelectric point Bio-Rad method, gOμV of canine osteocalcin was applied to a 70% polyacrylamide gel at 300V,
Electrophoresis was performed for 111 hours at 30°C, precipitated with 725% trichloroacetic acid, and gel scanner (Isco mode)
When measuring the U absorption of 2 g Opm with 3 g of Otsu, P
I=3.9.
試験例/
犬のオステオカルシン抗体の調製
犬のオステオカルシン(3〜)ヲ牛血清アルブミン(B
sA)(10〜)とグルクルアルデヒドを用いる常法t
こより架橋反応せしめ、セファデックスG−100カラ
ムを用いて精製し、/2〜のオステオカルシン−B S
A 結合体の免疫原ヲ得り。Test example/Preparation of canine osteocalcin antibody Canine osteocalcin (3~) Bovine serum albumin (B
sA) Conventional method using (10~) and gluculaldehyde
This was subjected to a cross-linking reaction and purified using a Sephadex G-100 column to obtain osteocalcin-B S of /2~
A. Obtaining the immunogen of the conjugate.
この/m’j/ml(生理食塩水)を等量のコンブIJ
−トフロイントアジュバントと共(こ乳化させ、家兎
またはヤギに4回免疫した後、常法によりそれぞれの抗
体を含有する抗血清を得た。Add this /m'j/ml (physiological saline) to an equal amount of kelp IJ
- After emulsifying with Tofreund's adjuvant and immunizing rabbits or goats four times, antiserum containing each antibody was obtained by a conventional method.
試験例2
血中の大オステオカルシン測定法
サンプル血清100μtに杭大オステオカルシン家兎抗
体含有抗血清を緩衝液CO,0/ M リン酸に07%
ゲラチン、0/%NaN3.23 m M E D T
A−62Na、 0. / 3 M NaC1,0,/
%Tween20を含みpHを\\711に調製〕で7
000倍稀釈したもの100μtおよび緩衝液200μ
tを加え一夜放置する。これK green wood
−Hunter法(Biochem、J、、 g9
/ / II−/ 23 (/り乙3))の方法tこ従
って得た1当−オステオカルシン100A L (20
,000cpm )を加え、<Z℃で一麗夜放置後家兎
IgG液(/20pfl/m1)100pLおよびヤギ
抗家兎IgG抗血清100μtを加え、37℃で2時間
インキュベートした。反応液をグ℃で遠心分離<300
Orpm 30m1n)し、沈澱物の放射能をカウン
トした。一方上記サンプル血清10Oμtの代りをこ緩
衝液100μを中tこ犬オ/図中X−−−−Xで示す)
を作製し、これより上記血清中のオステオカルシン含量
を求めることが出来る。Test Example 2 Blood Osteocalcin Measurement Method 100 μt of sample serum was added with antiserum containing Hangyo Osteocalcin rabbit antibody in buffer CO, 0/M phosphoric acid, 07%.
Gelatin, 0/% NaN3.23 m M E D T
A-62Na, 0. /3M NaC1,0,/
%Tween20 and adjusted the pH to \\711] to 7
100μt of 000x dilution and 200μt of buffer
Add t and leave overnight. This is green wood
-Hunter method (Biochem, J, g9
/ / II-/ 23 (/RI Otsu 3)) Method t 1-Osteocalcin 100A
,000 cpm) and left overnight at <Z°C, 100 pL of rabbit IgG solution (/20 pfl/ml) and 100 μt of goat anti-rabbit IgG antiserum were added and incubated at 37°C for 2 hours. Centrifuge the reaction at <300 °C.
Orpm 30mln), and the radioactivity of the precipitate was counted. On the other hand, instead of 100μt of the above sample serum, 100μt of this buffer solution was added (indicated by X---X in the figure).
From this, the osteocalcin content in the serum can be determined.
試験例3
エルカトニン、EGFl h−PTH(/−311)、
h−インスリン、h−カルシトニンヲ緩衝液10011
1中に、それぞれ/ ”g+ 3ng、10ng、 夕
Ong、1100nを含有するサンプルを使用し、試験
例ノで記した手順に従い、犬のオステオカルシンの家兎
抗体との免疫交叉反応性を調べた所、第1図(図中X−
−−Xi本発明ペプチド、○□○;エルカトニン、ロー
−−−一口、EGF、・−−−・、h−PTH(/−3
Il)、△・・・−△;h−インスリン、ム一−−4H
h CTを示す。)をこ示すように、大オステオカル
シンと選択的tこ反応し、エルカトニン、EGF、h−
PTH(/ −一 g −
311)、h−インスリン、h−カルシトニンとは交叉
反応を示さなかった。Test Example 3 Elcatonin, EGFL h-PTH (/-311),
h-insulin, h-calcitonin buffer 10011
Immune cross-reactivity of canine osteocalcin with domestic rabbit antibodies was investigated using samples containing 3 ng, 10 ng, 1100 n, and 1100 n of canine osteocalcin in Test Example 1, respectively. , Figure 1 (X- in the figure)
--Xi peptide of the present invention, ○□○; elcatonin, low --- mouth, EGF, ・---, h-PTH (/-3
Il), △...-△; h-insulin, mu--4H
h CT is shown. ), as shown, selectively reacts with large osteocalcin, elcatonin, EGF, h-
No cross-reactivity was shown with PTH (/-1 g-311), h-insulin, and h-calcitonin.
発明の効果 度を測定するのに有用な物質である。Effect of the invention It is a useful substance for measuring temperature.
第1図は、本発明ペプチドのラジオイムノアッセイの標
準曲線及び交叉反応性を示す。FIG. 1 shows the standard curve and cross-reactivity of radioimmunoassay of the peptide of the present invention.
Claims (1)
、AspはL−アスパラギン酸、SerはL−セリン、
Glyはグリシン、AlaはL−アラニン、ProはL
−プロリン、Glaはγ−カルボキシグルタミン酸、L
ysはL−リジン、ArgはL−アルギニン、Valは
L−バリン、CysはL−システイン、AsnはL−ア
スパラギン、HisはL−ヒスチジン、IleはL−イ
ソロイシン、PheはL−フェニルアラニンを示す) で表されるペプチドまたはその塩。(1) Formula [There is an amino acid sequence] (In the formula, Tyr is L-tyrosine, Leu is L-leucine, Asp is L-aspartic acid, Ser is L-serine,
Gly is glycine, Ala is L-alanine, Pro is L
- Proline, Gla is γ-carboxyglutamic acid, L
ys is L-lysine, Arg is L-arginine, Val is L-valine, Cys is L-cysteine, Asn is L-asparagine, His is L-histidine, He is L-isoleucine, and Phe is L-phenylalanine) A peptide represented by or a salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60107884A JPH0633317B2 (en) | 1985-05-20 | 1985-05-20 | New peptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60107884A JPH0633317B2 (en) | 1985-05-20 | 1985-05-20 | New peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61263999A true JPS61263999A (en) | 1986-11-21 |
JPH0633317B2 JPH0633317B2 (en) | 1994-05-02 |
Family
ID=14470519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60107884A Expired - Lifetime JPH0633317B2 (en) | 1985-05-20 | 1985-05-20 | New peptide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0633317B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63209596A (en) * | 1987-02-26 | 1988-08-31 | Takara Shuzo Co Ltd | Monoclonal antibody and use thereof |
JPH01160493A (en) * | 1987-12-18 | 1989-06-23 | Takara Shuzo Co Ltd | Monoclonal antibody and use thereof |
WO1990009587A1 (en) * | 1989-02-10 | 1990-08-23 | Teijin Limited | Immunoassay of human osteocalcin, reagent and kit therefor, antihuman osteocalcin antibody, hybridoma producing said antibody, and method of producing said antibody |
-
1985
- 1985-05-20 JP JP60107884A patent/JPH0633317B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63209596A (en) * | 1987-02-26 | 1988-08-31 | Takara Shuzo Co Ltd | Monoclonal antibody and use thereof |
JPH01160493A (en) * | 1987-12-18 | 1989-06-23 | Takara Shuzo Co Ltd | Monoclonal antibody and use thereof |
WO1990009587A1 (en) * | 1989-02-10 | 1990-08-23 | Teijin Limited | Immunoassay of human osteocalcin, reagent and kit therefor, antihuman osteocalcin antibody, hybridoma producing said antibody, and method of producing said antibody |
Also Published As
Publication number | Publication date |
---|---|
JPH0633317B2 (en) | 1994-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Palmer et al. | Dissociation of rabbit γ-globulin into half-molecules after reduction of one labile disulfide bond | |
Blum et al. | Comparative properties of vertebrate parvalbumins. | |
Jackson et al. | A comparison of the major apolipoprotein from pig and human high density lipoproteins | |
Farmer et al. | Purification and properties of teleost growth hormone | |
US4423034A (en) | Process for the preparation of antibodies | |
Gould et al. | Isolation and partial characterization of two anti-A hemagglutinins from P. lunatus | |
FR2503145A1 (en) | PEPTIDES RELATING TO HUMAN INTERFERONS, ANTIBODIES OBTAINED FROM THESE PEPTIDES AND ADSORBENTS OBTAINED FROM THESE ANTIBODIES | |
Jagschies et al. | Bovine fatty acid binding proteins: Isolation and characterisation of two cardiac fatty acid binding proteins that are distinct from corresponding hepatic proteins | |
Goodman et al. | Purification and characterization of a juvenile hormone binding protein from the hemolymph of the fourth instar tobacco hornworm, Manduca sexta | |
Corvol et al. | Large scale purification of hog renin. Physicochemical characterization. | |
Dilley et al. | Changes in proteins of the human lens in development and aging | |
Dahl et al. | Heterogeneity of the glial fibrillary acidic protein in gliosed human brains | |
Lilja et al. | Characterization of the predominant basic protein in human seminal plasma, one cleavage product of the major seminal vesicle protein | |
US4522751A (en) | Method for producing a preparation containing factor VIII (AHF) | |
Goldstein | Radioimmunoassay for thymopoietin | |
US4348316A (en) | New protein PP15, a process for its preparation and its use | |
Pihko et al. | Rabbit α-fetoprotein: Immunochemical purification and partial characterization | |
Foster et al. | Elastin biosynthesis in chick embryonic lung tissue. Comparison to chick aortic elastin | |
Bloemendal et al. | Isolation and properties of α-crystallin from the bovine lens | |
Porter | Neonatal hepatic mitochondrocuprein: IV. Sulfitolysis of the cystine-rich crude copper protein and isolation of a peptide containing more than 35% half-cystine | |
GB2062644A (en) | Glucagon fragment and utility hereof | |
PT90369B (en) | PROCESS FOR THE PREPARATION OF MONOCLONAL ANTIBODIES FOR SELECTIVE IMMUNOLOGICAL DETERMINATION OF INTACT (TYPE III) PROCOLAGENE AND PROCOLAGENE (TYPE III) PEPTIDE IN CORPORATE FLUIDS AND DETERMINATION PROCEDURE USING THESE ANTIBODIES | |
JPS61263999A (en) | Novel peptide | |
Heizmann et al. | The Purification, Characterization and Localization of a Parvalbumin‐Like Protein from Chicken‐Leg Muscle | |
Chersi et al. | Isolation, chemical and immunologic characterization of κ-and λ-type light chains from IgG of normal rabbits with b9 allotype |